Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

18.19 +0.88 (+5.08%)
Streaming Delayed Price Updated: 11:27 AM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months
Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy. 
Via Benzinga
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’
Via Stocktwits
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment
Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug. 
Via Investor's Business Daily
Why Is Arcus Biosciences Stock Trading Higher On Monday?
Arcus Biosciences reports casdatifan monotherapy data in renal cancer, showing a 35% response rate and median progression-free survival not yet reached. 
Via Benzinga
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
What to Expect from Arcus Biosciences's Earnings
 
Via Benzinga
Earnings Scheduled For February 25, 2025
 
Via Benzinga
Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus
On CNBC's Mad Money Lightning Round, Jim Cramer endorsed buying Uranium Energy and called Arcus Biosciences a speculative play. 
Via Benzinga
Gilead Lifts Annual Outlook As Yeztugo Launch Nears
Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology drug sales. 
Via Benzinga
Arcus (RCUS) Q2 Revenue Jumps 310%
Via The Motley Fool
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts
 
Via Benzinga
Unveiling 5 Analyst Insights On Arcus Biosciences
 
Via Benzinga
Where Arcus Biosciences Stands With Analysts
 
Via Benzinga
Demystifying Arcus Biosciences: Insights From 4 Analyst Reviews
 
Via Benzinga
Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Forecasting The Future: 5 Analyst Projections For Arcus Biosciences
 
Via Benzinga
Arcus Biosciences Shares Are Down Today: What's Going On?
Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock offering. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Breaking Down Arcus Biosciences: 4 Analysts Share Their Views
 
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences
 
Via Benzinga
Ericsson Posts Weak Results, Joins East West Bancorp And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q2 2024
RCUS stock results show that Arcus Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies
Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q1 2024
RCUS stock results show that Arcus Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS